End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
32.63 CNY | +0.09% | +0.43% | +4.82% |
May. 08 | Nomura Adjusts New China Life’s Price Target to 30.01 Yuan From 33.07 Yuan, Keeps at Neutral | MT |
May. 08 | Nomura Adjusts New China Life’s Price Target to HK$20.29 From HK$23.70, Keeps at Buy | MT |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 60% by 2026.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company appears to be poorly valued given its net asset value.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.82% | 11.72B | C | ||
+13.33% | 80B | B- | ||
+10.00% | 51.49B | B+ | ||
+4.25% | 48.79B | B | ||
+21.07% | 46.12B | B+ | ||
+14.24% | 42.3B | B+ | ||
+29.18% | 41.03B | B | ||
+1.03% | 29.42B | B | ||
-2.87% | 29.33B | B- | ||
-10.71% | 27.19B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 601336 Stock
- Ratings New China Life Insurance Company Ltd.